Literature DB >> 25454379

Colchicine for pericarditis.

Massimo Imazio1.   

Abstract

Colchicine is one of the oldest available drugs. It has been used for centuries to treat and prevent gouty attacks and more recently to prevent attacks of autoinflammatory diseases such as Familial Mediterranean Fever. Its main mechanism of action is the capability to block the polymerization of tubulin, thus affecting the function of microtubules. The capability to concentrate in white blood cells, especially granulocytes, and interfere with their function explains its potentiality as an anti-inflammatory drug. Colchicine (0.5mg twice daily for patients >70kg or once daily for those weighing less) in addition to standard anti-inflammatory therapy, in either acute or recurrent pericarditis, may hasten the response to anti-inflammatory therapy and reduce the subsequent risk of recurrences. After exclusion of contraindication and appropriate dose adjustment, the drug is safe and well tolerated. The more common side effect is gastrointestinal intolerance occurring in 5-10% of cases and may be controlled by dose reduction or temporary discontinuation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25454379     DOI: 10.1016/j.tcm.2014.09.011

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  5 in total

1.  Postpericardiotomy syndrome after cardiac surgery.

Authors:  Joonas Lehto; Tuomas Kiviniemi
Journal:  Ann Med       Date:  2020-05-02       Impact factor: 4.709

Review 2.  Recurrent pericarditis: new and emerging therapeutic options.

Authors:  Massimo Imazio; George Lazaros; Antonio Brucato; Fiorenzo Gaita
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

3.  The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.

Authors:  Jianhong Yang; Wei Yan; Yamei Yu; Yuxi Wang; Tao Yang; Linlin Xue; Xue Yuan; Caofeng Long; Zuowei Liu; Xiaoxin Chen; Mengshi Hu; Li Zheng; Qiang Qiu; Heying Pei; Dan Li; Fang Wang; Peng Bai; Jiaolin Wen; Haoyu Ye; Lijuan Chen
Journal:  J Biol Chem       Date:  2018-04-24       Impact factor: 5.157

4.  Colchicine inhibits ROS generation in response to glycoprotein VI stimulation.

Authors:  G J Pennings; C J Reddel; M Traini; H Campbell; V Chen; L Kritharides
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

5.  Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome.

Authors:  Leon L Lutschinger; Angelos G Rigopoulos; Peter Schlattmann; Marios Matiakis; Daniel Sedding; Paul Christian Schulze; Michel Noutsias
Journal:  BMC Cardiovasc Disord       Date:  2019-09-02       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.